(this["webpackJsonpakqa-ui-test"]=this["webpackJsonpakqa-ui-test"]||[]).push([[9],{27:function(e,a,s){},57:function(e,a,s){"use strict";s.r(a);s(1);var c=s.p+"static/media/Group 29612145.22ba7465.webp",t=s.p+"static/media/Group 29612146.5a9ee0ba.webp",i=s.p+"static/media/Group 29612147.bd1eca83.webp",n=s(3),p=s.n(n),r=(s(27),s(0));a.default=function(){return Object(r.jsx)("div",{className:"packages-page__main-containers",children:Object(r.jsxs)("div",{className:"packages-page__main-wrapper",children:[Object(r.jsx)(p.a,{left:!0,children:Object(r.jsxs)("div",{className:"packages-page__content-wrapper",children:[Object(r.jsx)("img",{className:"packages-page__package-image",src:c,alt:"package"}),Object(r.jsxs)("p",{className:"packages-page__title",children:[" ","Long term sustained improvement"," "]}),Object(r.jsxs)("p",{className:"packages-page__main-content",children:[" ","9 out of 10 respondents experienced sustained disease control in clinical trials 10, providing sustained improvements in the burden of disease(1,2, 1, 8*\u2020\u2021)."," "]}),Object(r.jsxs)("p",{className:"packages-page__tail-content",children:[" ","See efficacy and trial data"," "]})]})}),Object(r.jsx)(p.a,{right:!0,children:Object(r.jsxs)("div",{className:"packages-page__content-wrapper",children:[Object(r.jsx)("img",{src:t,alt:"package",className:"packages-page__package-image"}),Object(r.jsxs)("p",{className:"packages-page__title",children:[" ","Improvements in the burden of disease"]}),Object(r.jsxs)("p",{className:"packages-page__main-content",children:[" ","Patients in clinical trials saw an improvement in Quality of Life with early symptom relief and sustained improvements in burden of disease from week 16 to 32(12,13)."," "]}),Object(r.jsxs)("p",{className:"packages-page__tail-content",children:[" ","Learn more about quality of life improvements"," "]})]})}),Object(r.jsx)(p.a,{left:!0,children:Object(r.jsxs)("div",{className:"packages-page__content-wrapper",children:[Object(r.jsx)("img",{src:i,alt:"package",className:"packages-page__package-image"}),Object(r.jsx)("p",{className:"packages-page__title",children:" Good safety profile"}),Object(r.jsx)("p",{className:"packages-page__main-content",children:"The overall frequency and severity of adverse events with Adtralza\xae were comparable to placebo at 16 weeks* and 52 weeks(19)."}),Object(r.jsx)("p",{className:"packages-page__tail-content",children:" See safety profile "})]})})]})})}}}]);
//# sourceMappingURL=9.83309a4f.chunk.js.map